Action Point Financial Planning’s Cytokinetics CYTK Stock Holding History

Action Point Financial Planning’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.56K	Buy	+32	New	+$2.3K	﹤0.01%	2140

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Action Point Financial Planning's CYTK Position: Q2 2026 in Review

Action Point Financial Planning opened a new position in Cytokinetics (CYTK) in Q2 2026: 32 shares worth $2.56K. The stake represents ﹤0.01% of the portfolio and ranks #2140 among its holdings.

479 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Action Point Financial Planning held 32 shares of Cytokinetics worth $2.56K as of Q2 2026.
Cytokinetics was a new Action Point Financial Planning position in Q2 2026.
Cytokinetics made up ﹤0.01% of Action Point Financial Planning's portfolio in Q2 2026, its #2140 holding.
479 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Action Point Financial Planning's 13F filing for Q2 2026, filed 14 Aug 2026.